Relative Expression of CMyc MRNA in Human Glioma Cells and Its Relationship with the Degree of Malignancy

Relative Expression of cMyc85Vol. 5, No. 2, Agustus 2017RESEARCH ARTICLERelative Expression of cMyc mRNA in Human Glioma Cells and its Relationship with the Degree of Malignancy Fidinny I. Hamid,1 Novi S. Hardiany,2* Febrial Hikmah,3 Syaiful Ichwan41Undergraduate Program FM Universitas Indonesia2Department of Biochemistry and Molecular Biology, FM Universitas Indonesia3Biomedical Sciences Program FM Universitas Indonesia4Department of Neurosurgery FM Universitas Indonesia -Dr Cipto Mangunkusumo General Hospital*Corresponding author: [email protected] 10 April 2016; Accepted 23 Agustus 2017DOI: 10.23886/ejki.5.7467AbstractPluripotency of cMyc genes may be one factor for the high glial cell differentiation in glioma thus it can become an alternative therapeutic target. The objective of the study is toanalyze the cMyc mRNA expression and its relationship with the degrees of glioma Malignancy. This is a cross-sectional study from 20 glioma samples with different degree of Malignancy from Dr. Cipto Mangunkusumo General Hospital, Jakarta during the period of October 2014 until February 2015. The mRNA obtained from glioma samples are converted to cDNA and then amplified. Relative quantification of cMyc mRNA expression is measured by calculating the cycle threshold values of Real Time RT PCR and normalized towards 18s rRNA to predict the relationship between the expression of cMyc and the degree of Malignancy. The cMyc expression is increased in accordance with the tumor grade. The cMyc expressions in high grade glioma are 17424.23 folds higher when calibrated to the normal cell, whereas the genes in lower grade tumors are expressed with the rate of 6167.35. Although the values obtained are not statistically significant, this research has strengthened molecular diagnosis, specifically pluripotency as the factor that gives a greater prognostic relevance than the histopathologic diagnosis. As a conclusion, there is a clinical tendency where the relative mRNA expression was higher in in glioma cMyc high degrees compared with low-grade glioma, however it is not statistically significant

Relative Expression of cMyc mRNA in Human Glioma Cells and its Relationship with the Degree of Malignancy

Relative Expression of cMyc85Vol. 5, No. 2, Agustus 2017RESEARCH ARTICLERelative Expression of cMyc mRNA in Human Glioma Cells and its Relationship with the Degree of Malignancy Fidinny I. Hamid,1 Novi S. Hardiany,2* Febrial Hikmah,3 Syaiful Ichwan41Undergraduate Program FM Universitas Indonesia2Department of Biochemistry and Molecular Biology, FM Universitas Indonesia3Biomedical Sciences Program FM Universitas Indonesia4Department of Neurosurgery FM Universitas Indonesia -Dr Cipto Mangunkusumo General Hospital*Corresponding author: [email protected] 10 April 2016; Accepted 23 Agustus 2017DOI: 10.23886/ejki.5.7467AbstractPluripotency of cMyc genes may be one factor for the high glial cell differentiation in glioma thus it can become an alternative therapeutic target. The objective of the study is toanalyze the cMyc mRNA expression and its relationship with the degrees of glioma malignancy. This is a cross-sectional study from 20 glioma samples with different degree of malignancy from Dr. Cipto Mangunkusumo General Hospital, Jakarta during the period of October 2014 until February 2015. The mRNA obtained from glioma samples are converted to cDNA and then amplified. Relative quantification of cMyc mRNA expression is measured by calculating the cycle threshold values of Real Time RT PCR and normalized towards 18s rRNA to predict the relationship between the expression of cMyc and the degree of malignancy. The cMyc expression is increased in accordance with the tumor grade. The cMyc expressions in high grade glioma are 17424.23 folds higher when calibrated to the normal cell, whereas the genes in lower grade tumors are expressed with the rate of 6167.35. Although the values obtained are not statistically significant, this research has strengthened molecular diagnosis, specifically pluripotency as the factor that gives a greater prognostic relevance than the histopathologic diagnosis. As a conclusion, there is a clinical tendency where the relative mRNA expression was higher in in glioma cMyc high degrees compared with low-grade glioma, however it is not statistically significant

Nigella sativa L. as immunomodulator and preventive effect on renal tissue damage of lupus mice induced by pristane

Abstract Introduction: Nigella sativa L. is an herbal plant with Thimoquinone as the main therapeutic properties. This plants has been shown to cure for various diseases and affected the immune system by modulating cytokines and T regulatory cell (Treg) sot that able to prevent renal injury in several diseases, but studies on Systemic Lupus Erythematous are still rare. Objective: This study aimed to investigate immunomodulation and preventive effects of Nigella sativa L. on renal tissue damage in Pristane induced Lupus (PIL)-mice model. Methods: This true experimental study included 48 female Balb/C mice, 38 mice were injected pristane intraperitoneally and waited 16 weeks to become lupus model. Only 30 mice met the Systemic Lupus International Collaborating Clinics criteria. Ten healthy mice were used as control, 30 PIL mice model divided into 3 groups (placebo, steroid, Nigella sativa L.). At the end of 28 days of treatment, the mice were sacrificed to take a blood sample and kidney organ to evaluate the injury histopathologically. Results: The results showed that the cytokine expression Interleukin (IL) (IL-17, IL-6, IL-23) in the Nigella sativa L. group was the lowest. The highest absolute number of Tregs was the steroid group followed Nigella sativa L. group. Renal injury assessed histopathologically showed the Nigella sativa L. group was the lowest and almost close to normal. Conclusion: This study indicate that Nigella sativa L. has an immunomodulatory effect and can prevent kidney injury PIL-treated mice. We suggest that Nigella sativa L. may need to be considered for further research on its use as a complementary supplement in lupus patients

The journey to normal : panduan adaptasi kebiasaan baru pada masa pandemi Covid-19

Buku The Journey To Normal: Panduan Adaptasi Kebiasaan Baru Pada Masa Pandemi Covid-19 merupakan intisari dari panduan adaptasi kebiasaan baru yang telah dikeluarkan oleh Badan kesehatan Dunia (WHO) maupun Pemerintah Indonesia melalui Gugus Tugas Percepatan Penanganan Covid-19 Republik Indonesia. Seperti halnya yang sudah diketahui bersama, pandemic COVID-19 telah melanda hampir seluruh umat manusia di berbagai belahan dunia. Pada tanggal 12 Februari 2020, WHO resmi menetapkan penyakit novel coronavirus pada manusia ini dengan sebutan Coronavirus Disease (COVID19). Pada tanggal 11 Maret 2020, WHO sudah menetapkan COVID-19 sebagai pandemi. Panduan ini ditujukan bagi seluruh cicitas akademika penyelenggara pendidikan tinggi di Indonesia. Berisi tentang pengetahuan dasar infeksi SARS-CoV-2, Ptofisiologi, tatalaksana dan pencegahan serta rehabilitasi pasien Covid-19. Di dalam buku ini juga, penulis menyediakan panduan bagi institusi penyelenggara pendidikan tinggi dalam menyelenggarakan pembelajaran secara luring (luar jaringan). Pimpinan institusi dapat mengaplikasikan prosedur dan kegiatan mitigasi infeksi covid-19 di tempat masing-masing